How did the COVID-19 pandemic affect access to condoms, chlamydia and HIV testing, and cervical cancer screening at a population level in Britain? (Natsal-COVID).


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
06 2023
Historique:
received: 06 05 2022
accepted: 16 07 2022
medline: 19 5 2023
pubmed: 19 8 2022
entrez: 18 8 2022
Statut: ppublish

Résumé

To investigate how differential access to key interventions to reduce STIs, HIV and their sequelae changed during the COVID-19 pandemic. British participants (18-59 years) completed a cross-sectional web survey 1 year (March-April 2021) after the initial lockdown in Britain. Quota-based sampling and weighting resulted in a quasi-representative population sample. We compared Natsal-COVID data with Natsal-3, a household-based probability sample cross-sectional survey (16-74 years) conducted in 2010-2012. Reported unmet need for condoms because of the pandemic and uptake of chlamydia testing/HIV testing/cervical cancer screening were analysed among sexually experienced participants (18-44 years) (n=3869, Natsal-COVID; n=8551, Natsal-3). ORs adjusted for age and other potential confounders describe associations with demographic and behavioural factors. In 2021, 6.9% of women and 16.2% of men reported unmet need for condoms because of the pandemic. This was more likely among participants: aged 18-24 years, of black or black British ethnicity, and reporting same-sex sex (past 5 years) or one or more new relationships (past year). Chlamydia and HIV testing were more commonly reported by younger participants, those reporting condomless sex with new sexual partners and men reporting same-sex partners; a very similar distribution to 10 years previously (Natsal-3). However, there were differences during the pandemic, including stronger associations with chlamydia testing for men reporting same-sex partners; with HIV testing for women reporting new sexual partners and with cervical screening among smokers. Our study suggests differential access to key primary and secondary STI/HIV prevention interventions continued during the first year of the COVID-19 pandemic. However, there was not strong evidence that differential access has changed during the pandemic when compared with 2010-2012. While the pandemic might not have exacerbated inequalities in access to primary and secondary prevention, it is clear that large inequalities persisted, typically among those at greatest STI/HIV risk.

Identifiants

pubmed: 35981863
pii: sextrans-2022-055516
doi: 10.1136/sextrans-2022-055516
pmc: PMC10313967
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-267

Subventions

Organisme : Chief Scientist Office
ID : SPHSU18
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212931/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00022/3
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet Public Health. 2022 Jan;7(1):e4-e5
pubmed: 34995542
BMJ Sex Reprod Health. 2023 Jan;49(1):12-20
pubmed: 35444001
Sex Transm Infect. 2014 Mar;90(2):84-9
pubmed: 24277881
BMJ Sex Reprod Health. 2021 Oct;47(4):269-276
pubmed: 33707178
Lancet. 2013 Nov 30;382(9907):1795-806
pubmed: 24286785
Wellcome Open Res. 2021 Aug 16;6:209
pubmed: 35495088
BMC Public Health. 2016 Jul 07;16:525
pubmed: 27386950
Lancet Public Health. 2022 Jan;7(1):e36-e47
pubmed: 34995541
Sex Transm Infect. 2022 Nov;98(7):537-538
pubmed: 34548415
Sex Transm Infect. 2022 Nov;98(7):469-477
pubmed: 34916335
Lancet Public Health. 2017 Oct 03;2(10):e458-e472
pubmed: 29057382
Int J Cancer. 2006 Mar 15;118(6):1481-95
pubmed: 16206285

Auteurs

Emily Dema (E)

Institute for Global Health, University College London, London, UK emily.dema.19@ucl.ac.uk.

Pam Sonnenberg (P)

Institute for Global Health, University College London, London, UK.

Jo Gibbs (J)

Institute for Global Health, University College London, London, UK.

Anne Conolly (A)

Institute for Global Health, University College London, London, UK.
Health and Biomedical Surveys, NatCen Social Research, London, UK.

Malachi Willis (M)

Social and Public Health Sciences Unit, University of Glasgow MRC/CSO, Glasgow, UK.

Julie Riddell (J)

Social and Public Health Sciences Unit, University of Glasgow MRC/CSO, Glasgow, UK.

Raquel Bosó Pérez (R)

Social and Public Health Sciences Unit, University of Glasgow MRC/CSO, Glasgow, UK.

Andrew J Copas (AJ)

Institute for Global Health, University College London, London, UK.

Clare Tanton (C)

Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Chris Bonell (C)

Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Clarissa Oeser (C)

Institute for Global Health, University College London, London, UK.

Soazig Clifton (S)

Institute for Global Health, University College London, London, UK.
Health and Biomedical Surveys, NatCen Social Research, London, UK.

Magnus Unemo (M)

Department of Laboratory Medicine, Örebro University Hospital, Orebro, Sweden.

Catherine H Mercer (CH)

Institute for Global Health, University College London, London, UK.

Kirstin R Mitchell (KR)

Social and Public Health Sciences Unit, University of Glasgow MRC/CSO, Glasgow, UK.

Nigel Field (N)

Institute for Global Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH